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It is widely accepted that changes underlying depression and antidepressant-like effects involve not only alterations in the levels
of neurotransmitters as monoamines and their receptors in the brain, but also structural and functional changes far beyond.
During the last two decades, emerging theories are providing new explanations about the neurobiology of depression and the
mechanism of action of antidepressant strategies based on cellular changes at the CNS level.The neurotrophic/plasticity hypothesis
of depression, proposed more than a decade ago, is now supported by multiple basic and clinical studies focused on the role of
intracellular-signalling cascades that govern neural proliferation and plasticity. Herein, we review the state-of-the-art of the changes
in these signalling pathways which appear to underlie both depressive disorders and antidepressant actions. We will especially
focus on the hippocampal cellularity and plasticity modulation by serotonin, trophic factors as brain-derived neurotrophic factor
(BDNF), and vascular endothelial growth factor (VEGF) through intracellular signalling pathways—cAMP, Wnt/𝛽-catenin, and
mTOR. Connecting the classic monoaminergic hypothesis with proliferation/neuroplasticity-related evidence is an appealing and
comprehensive attempt for improving our knowledge about the neurobiological events leading to depression and associated to
antidepressant therapies.
1. Introduction
Major depressive disorder (MDD) constitutes the first leading
cause of years lived with disability [1], and its incidence
is on the rise globally. Yet, until recently, little was known
about its pathogenesis, as these conditions are not associated
with relevant brain alterations or clear animal models for
spontaneous recurrent mood episodes.
The clinical phenomenology of major depression impli-
cates brain neurotransmitter systems involved in the regu-
lation of mood, anxiety, fear, reward processing, attention,
motivation, stress responses, social interaction, and neu-
rovegetative function [2]. MDD is associated with blunted
reactivity to both positively and negatively stimuli [3]; thus,
the decline in hedonic responses may be related to general-
ized affective insensitivity, instead of deficits in the capacity to
feel pleasure at the level of basic sensory experience [4]. From
the middle of the last century, a great effort has been made to
elucidate the brain areas involved in emotion control and in
the pathophysiology of mood disorders. Animal and human
studies have indicated the involvement of the limbic system—
including the hippocampal formation, cingulate gyrus, and
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anterior thalamus—the amygdala and different cortical struc-
tures as well as the hypothalamus in these processes [5, 6].
These structures are connected in two main networks: the
“orbital” and the “medial prefrontal networks.” The orbital
network appears to function both as a system for integration
of multimodal stimuli and as a system for assessment of the
value of those stimuli, and, probably, the support of abstract
assessment of reward. The medial network is probably more
significant for mood disorders [7].
In depressed subjects, the structures of the medial pre-
frontal network have been shown to contain alterations in
gray matter volume, cellular elements, neurophysiological
activity, receptor pharmacology, and gene expression. Dys-
function within this system underlies the disturbances in
emotional behavior and other cognitive aspects of the major
depressive disorder. Treatments for depression, involving
pharmacological, neurosurgical, and deep brain stimulation
methods, appear to suppress pathological activity within
the components of medial prefrontal network such as the
subgenual anterior cingulate cortex, ventromedial frontal
cortex, striatum, and amygdala [6].
Although the causes of MDD are not yet completely
known, genetic factors appear to play an important role
although other factors deal with acute or chronic stress, child-
hood trauma, viral infections, and others [12, 13]. Regarding
genetic causes, certain polymorphisms in genes related to
the serotonergic system as the serotonin transporter, the
brain-derived neurotrophic factor, the monoamine oxidase
A, or the tryptophan hydroxylase 1, may increase the risk
for depression or the vulnerability to stress [14]. Not all
the studies published to date have found gene-environment
interactions; however, the combination of both factors seems
to predict more accurately a person’s risk to suffer from
major depressive disorder better than genes or environment
alone.
The discovery that some drugs as iproniazid and
imipramine exert an antidepressant effect dates back to the
1950s [15]. In 1965, it was shown that these drugs act through
the monoaminergic system by increasing the brain levels
of those monoamines [16]. These observations led to the
development of the classical “monoaminergic hypothesis of
depression,” which proposes that lowmonoamine brain levels
in depressed individuals are responsible for this pathology.
The classic antidepressants that increase monoamine neu-
rotransmitters in the synaptic cleft are generally used for
first-line treatment. However, the clinical benefit of these
treatments is not immediate, taking 3-4 weeks to obtain
a full response. Other therapeutic problems of currently
used antidepressant drugs include relapses, drug side effects,
incomplete resolution, residual symptoms, and drug resis-
tance.
Traditionally, research in the neurobiology of major
depressive disorder has been focused on monoamines. How-
ever, several lines of evidence [17] have led to the conclusion
that the abnormalities associated to depression go beyond
monoaminergic neurotransmission: thus, the development of
better antidepressants will surely depend on the discovery
and understanding of new cellular targets. In this regard,
in the late 90’s a new hypothesis has tried to explain major
depression based on molecular mechanisms of neuroplastic-
ity [18].
The “neuroplasticity hypothesis” was postulated based on
several findings: first, stress decrease hippocampal neuro-
genesis and synaptic plasticity in prefrontal cortex (PFCx)
[19–22]. Moreover, most known antidepressant therapies
stimulate the proliferation of hippocampal progenitor cells,
which constitutes the first stage of adult hippocampal neu-
rogenesis [23]. However, the contribution of hippocampal
neurogenesis to the pathogenesis of depression is far from
being fully understood. Second, hippocampal morphologic
analyses in depressed patients reveal volume loss and gray
matter alterations.While some studies suggest that decreased
adult neurogenesis could be responsible for such fluctuat-
ing changes, others show that the hippocampal volumetric
reductions could be due to changes in neuropil, glial number,
and/or dendritic complexity, and not necessarily to a cell
proliferation decrease [24]. Third, different neuroplasticity-
and proliferation-related intracellular pathways appear to
be involved in the antidepressants’ action as brain-derived
neurotrophic factor (BDNF) [25], 𝛽-catenin [10, 26], or the
mammalian target of rapamycin (mTOR) [27].
2. Cell Proliferation and Plasticity
Role in Mood Disorders and
Antidepressant Treatments
Dentate gyrus proliferation is decreased by stress [19–22],
and in several animal models of depression as unpredictable
stress, chronic administration of corticosterone, olfactory
bulbectomy, or maternal deprivation [22, 28–31]. This loss in
cell proliferation is correlated with a decreased hippocampal
volume [32–34]. Hippocampal proliferation decrease is also
observed in other diseasemodels such as diabeticmice,which
present a high incidence of depression reported in individuals
with that primary illness [35]. In these animals, the reduced
hippocampal proliferation is reversed with chronic antide-
pressant treatments [35]. In animals subjected to acute or
chronic stress, a period of at least 24 h or 3weeks, respectively,
is required to get a recovery of the cellular proliferation [29].
However, although all these changes have been extensively
studied, major depression is not generally considered as
“hippocampal disorder.”
It is unlikely that impaired adult hippocampal neuroge-
nesis alone may fully explain the neuropathology of major
depression. In this sense, other studies have addressed cel-
lular proliferation in anatomical structures quite relevant to
depressive disorders, such as prefrontal cortex and amygdala,
by using animal models of depression. Thus, medial frontal
cortex presents a reduction in cell proliferation [36], down-
regulation of genes implicated in cell proliferation [37, 38],
decreased cell growth and survival, and apoptosis inhibition
[38]. Structures such as amygdala present an opposite pattern,
with an increase in neuronal dendrite length in stress models
[39]. Chronic administration of antidepressants leads to an
increased proliferation in prefrontal cortex [36, 40] although
the fate of the new generated cells goes toward the formation
of glia rather than neurons, in contrast to hippocampus
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[36]. No data are available regarding antidepressant effects
on amygdalar cell proliferation; however, this structure has
been involved in the negative control of the hippocampal
cell survival induced by antidepressant treatments, based on
the increased cell survival observed in hippocampus, after
the basolateral complex of the amygdale (BLA) lesion [41].
It is interesting to note that amygdala—implicated in fear-
related learning that impairs the memory processing of the
Hp-PFCx memory—shows an enhancement of LTP under
stress situations, which is not reverted by antidepressants.
Thus, antidepressants as tianeptine are able to restore the
normal functionality of Hp and PFCx under stress situations,
while the amygdala retains the ability to increase its activity
in the same stress conditions [42].
The disturbed adult hippocampal neurogenesis cannot
fully explain major depression. It could only be the most
conspicuous feature of a more fundamental type of cellular
plasticity, which could also govern the prefrontal cortex and
other regions. It has also been proposed that, in addition to
neural proliferation, changes in synaptic plasticity would also
be involved in the biological basis of depression [19], being
modulated by antidepressant treatments [43, 44]. PFCx is also
a region sensitive to stress-induced effects, with a reduction in
the number and length of spines [45] in apical dendrites of the
pyramidal cells in the medial prefrontal cortex area [46, 47],
as well as changes in the number, morphology, metabolism,
and function of glial cells, that produce changes in the glu-
tamatergic transmission, resulting in memory impairments
[48–51], and reduced synaptic plasticity in the Hp-PFCx
neuronal pathway [52]. The increase in extracellular gluta-
mate could be one of the reasons underlying the molecular
changes associated to stress [51]. However, while frontal
cortex and hippocampus are reduced and hypofunctional
in major depression, structures such as amygdala present
hypertrophy and hyperactivity. Changes in synaptic plasticity
will reflect a vulnerability to suffer a depression episode [39].
An increased apoptosis has also been related to a higher
risk of suffering major depression since increased cell death
in areas as dentate gyrus (DG), CA1, and CA4 areas of the
hippocampus, entorhinal cortex, and subiculum are reported
in studies using human postmortem brain samples though
this phenomenon does not seem to account for the hip-
pocampal volume reduction [53]. Animal studies also report
that acute stress increase hippocampal apoptosis [29], while
chronic stress induces no changes [29], increased apoptosis
in cortex [54, 55], or hippocampus [55]. Antidepressant
treatment decreases cell death by differentmechanisms, as the
activation of the expression of trophic factors (BDNF and its
receptor TrkB)which results in increased cell survival [56, 57]
or directly reducing cellular apoptosis in animal stressmodels
as reported for fluoxetine [28, 58].
It has been suggested that an increase in serotonin
levels mediates the raise in cell proliferation, while the
depletion of this neurotransmitter does not lead to an
immediate effect over the hippocampal cell division [59]. In
line with that, the direct or indirect modulation leads to an
increase in proliferation. Treatments exerting a direct action
over the serotonergic system include chronic but not acute
administration with drugs such as tricyclic antidepressants,
monoamine oxidase inhibitors (MAOI), serotonin-selective
reuptake inhibitors (SSRI), serotonin and noradrenaline
reuptake inhibitors (SNRI), and 5HT
4
agonists [8, 19, 20, 60–
65]. A nonpharmacological intervention such as the silencing
of the serotonin transporter (SERT) by RNAi in dorsal raphe
serotonergic neurons also leads to increased hippocampal
proliferation [66].The administration of other drugs, such as
lithium in combination with antidepressants as desipramine,
produces an increase in hippocampal proliferation [67] and
a decrease in apoptosis of hippocampal progenitor cells in
irradiated animals [68]. Treatments with antidepressants that
increase serotonin levels in brain act by targeting different
progenitor cell populations. Thus, chronic administration of
the SSRI fluoxetine [69] or subchronic treatment with a 5-
HT
4
agonist [8] increases cell proliferation and neurogenesis-
targeting amplifying neural progenitors (ANPs) (Figure 1)
while chronic electroconvulsive seizure (ECS) produces a
fast-acting effect targeting both quiescent neural progenitors
(QNPs) and ANPs [70]. An increased hippocampal prolifer-
ation as a consequence of chronic antidepressant treatment
has been proven necessary for some [71–73], but not all the
antidepressant-like effects in animals. The antidepressant-
like effects have been related to the increased hippocampal
proliferation [8, 71, 74], dendritic arborization, maturation,
and functional integration of newborn neurons [75]. How-
ever, other drugs with potential antidepressant action do
not mediate their effect through the activation of progenitor
cells division, since the complete elimination of hippocampal
proliferation by direct irradiation of this structure does not
block the antidepressant response promoted by the blockade
of drugs acting on other neurotransmitter systems as the
corticotrophin-releasing factor receptor (CRF) or arginine
vasopressin 1b (V1b) receptors [76].
3. Pathways Leading to Proliferation and
Neural Plasticity Changes That Exert
Antidepressant-Like Effect
Classically, the modulation of different neurotransmitter sys-
tems has been implicated in the mediation of the antidepres-
sant effects, and, for some of them, a link with proliferative or
plastic changes has been reported. The traditionally involved
neurotransmitter systems include the serotonergic, adrener-
gic, and dopaminergic ones, while others, such as the glu-
tamatergic and cannabinoid systems and the corticotropin-
releasing factor (CRF) system implicated in the secretion
of ACTH are acquiring increasing importance in the last
years. Here we will focus on the serotonergic receptors most
relevant to modulating neural proliferation and synaptic
plasticity processes.
3.1. Serotonergic Receptors. Serotonin has a positive role in
the regulation of hippocampal neurogenesis. The partial
lesion of dorsal and medial raphe nuclei, which results
in a decrease of serotonergic neurons that innervate the
dentate gyrus of the hippocampus and other projection areas
as cortex and amygdala, decreases the proliferation in the
subgranular zone of the dentate gyrus [132]. Several serotonin
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Figure 1: RS67333 increases the number of ANPs (b) and neuroblasts type 1 (c) that express 𝛽-catenin, but not total number of QNPs cells
(a). Photomicrographs illustrating 𝛽-catenin expression in neural progenitors (d), ANPs (e), and neuroblasts (f). The results are the Mean ±
S.E.M. ∗𝑃 < 0.05 versus vehicle. Bar: 10 𝜇M, modified from Pascual-Brazo et al., 2012 [8].
receptors have been involved in the antidepressant-induced
increase of cell proliferation in the hippocampus, together
with neurite outgrowth and cell survival in cells express-
ing these receptors [80]. However, other authors report a
lack of changes in proliferation and/or neurotrophic factors
expression after chronic treatment with the antidepressant
fluoxetine, questioning the importance of the serotonergic
system in hippocampal proliferation [133–135].
3.1.1. 5-𝐻𝑇
1𝐴
Receptors. The importance of this serotonergic
subtype in the effects of antidepressants has been shown in
studies in vivo using 3 day treatment with the 5-HT
1A agonist
8-OH-DPAT [77], and chronic administration of this drug
[74, 79, 80] that produce an increase in proliferation in the
subgranular zone (SGZ) of the hippocampus that depends
on the 5-HT
1A postsynaptic receptors. In studies using
hippocampal neural progenitors, the serotonin-mediated
increase in proliferation is blocked by the 5-HT
1A antagonist
WAY100,635 [78]. On the contrary, the acute administration
of 5-HT
1A antagonists produces a decrease of hippocampal
proliferation [136], or no changes after 14 days [79]. Knock out
animals for the 5-HT
1A receptor subtype present no changes
in basal proliferation compared to wild type animals [9, 71],
but present a decreased hippocampal cell survival [9]. The
5-HT
1A receptor subtype has been proven necessary for the
hippocampal proliferative effect of some antidepressants as
fluoxetine [71], although other drugs as imipramine, acting
on other neurotransmitter systems, increases hippocampal
proliferation in a 5-HT
1A-independentmanner [71] (Table 1).
3.1.2. 5-𝐻𝑇
2𝐴/𝐶
Receptors. Therole of the 5-HT
2A/C receptors
in the regulation of neurogenesis is less clear. The chronic
administration of 5-HT
2A antagonists as ketanserin [81], and
5-HT
2C antagonists as SB243,213 and S32006 [82], produce
the increase in hippocampal proliferation, while the acute
treatment with 5-HT
2A/C agonists or antagonists produce
no changes or a decrease in proliferation, respectively [74,
81]. Interestingly, the subchronic treatment with ketanserine
in combination with the SSRI fluoxetine increases a series
of synaptic plasticity markers as 𝛽-catenin and N-cadherin
present in the membrane fraction, together with BDNF gene
expression, however, hippocampal proliferation is not signif-
icantly modified [83]. The increased proliferation or synaptic
plasticity parallel the antidepressant-like effect observed for
the treatments with antagonists [83, 137, 138], while the
administration of 5-HT
2A agonist counteracts the effect
of SSRIs [137]. The blockade of 5-HT
2A receptor subtype
located in GABAergic interneurons produces the activation
of hippocampal pyramidal neurons [139] that modulates
dendritic activation and synaptic plasticity [140] (Table 1).
3.1.3. 5-HT
4
Receptors. In the last years, the 5-HT
4
receptor
subtype has been proven to have an outstanding role on the
depressive pathology. This receptor subtype density and sig-
naling cascade through cAMP are up-regulated in the frontal
cortex and caudate-putamen of depressed humans [141].
Chronic treatments with classical antidepressants produce a
desensitization of this subtype in structures as hippocampus
[97, 98]. In the last years, it has been described a short-
term antidepressant-like response mediated by 5-HT
4
partial
agonists [8, 64, 65], or when coadministered with classical
antidepressants [63]. The antidepressant effect of 5-HT
4
ago-
nist is mediated by an increase in hippocampal proliferation
in vivo [8, 64], together with other proliferative and plasticity
Neural Plasticity 5
Table 1: Role of the activation and blockade of the different serotonin receptor subtypes in neural proliferation and synaptic plasticity.
Serotonin
receptor
subtypes
Effect of pharmacological manipulation on hippocampal proliferation ko
Agonist Antagonist
Change Reference Change Reference Change Reference
5-HT1A
↑ proliferation (subchronic) [77] ↓ proliferation (acute) [78] = proliferation [9, 71]
= proliferation (chronic) [79]
↑ proliferation (chronic) [74, 79, 80]
blocks 5-HT-induced
proliferation [78] ↓ cell survival [9]
5-HT2A/2C = proliferation (+SSRI) [74]
↑ proliferation (chronic) [81, 82]
No data= proliferation (acute) [74, 81]
↑ plasticity markers and BDNF
(+SSRI, subchronic) [83]
5-HT4
↑ proliferation (subchronic) [8, 64] Blocks 5-HT-induced
proliferation [78]
No data
↑ plasticity markers and BDNF
(subchronic) [8, 63–65]
5-HT6 No data
= proliferation [84]
No data
↑ plasticity markers
(PSA-NCAM) [84]
5-HT7 No data ↑ proliferation (subchronic) [85] = proliferation [86]
↑ : increase; ↓ : decrease; ko: knock-out mice.
markers as 𝛽-catenin, Akt [8], BDNF [8, 65], phosphorylated
cAMP response element binding (CREB) protein [8, 63–65].
The 5-HT
4
implication in serotonin-induced hippocampal
proliferation has been observed blocking this receptor with
the 5-HT
4
antagonist DAU 6285 in primary hippocampal
progenitor cell cultures [78] (Table 1).
3.1.4. 5-HT
6
Receptors. The role of the 5-HT
6
receptor sub-
type in depression is not clear, but tricyclic antidepressants
as amitriptyline and atypical antidepressants as mianserin
have high affinity for this serotonin receptor subtype, acting
as antagonists [142]. Moreover, the expression of the 5-
HT
6
receptors is regulated by glucocorticoid levels [142].
This receptor subtype is present postsynaptically in brain
areas as cortex and hippocampus and is implicated in
learning and memory [142]. The action over this receptor to
date is contradictory since it has been published that both
antagonists and agonists exert antidepressant and anxiolytic
effects alone [142, 143] or enhance the beneficial effect when
combined with antidepressant drugs [144]. When locally
administered on hippocampus, 5-HT
6
antagonists produce
antidepressant-like effect [145]. However, this effect is not
mediated by increased neurogenesis but for an increase in
neural cell adhesion molecule polysialylation (PSA-NCAM)
that may mediate memory consolidation [84] through long-
term changes in synaptic plasticity [146] (Table 1).
3.1.5. 5-HT
7
Receptors. The 5-HT
7
receptor subtype is also
involved in the antidepressant effect. Recent studies have
shown that the blockade of the 5-HT
7
receptor subtype
produces antidepressant-like behaviour [147, 148]. This is
supported by studies in animal depression models as the
olfactory bulbectomy [85], the antidepressant-like behaviour
of knock-out mice for the 5-HT
7
receptor subtype [149], and
clinical data using the antagonist Lu AA21004 [150]. More-
over, a 7-day treatment with the 5-HT
7
antagonist SB-269970
produces an increase in proliferation in the subgranular zone
of the hippocampus [85] although changes in the number of
dividing cells do not appear in 5-HT
7
knock-out animals [86]
(Table 1).
3.2. Neurotrophic Factors. In an attempt to explain those
brain changes implicated on depression and/or antidepres-
sant effect that could not be included in the initialmonoamin-
ergic hypothesis of depression, it was postulated the so-
called “Neurotrophic hypothesis of Depression” that later
was revised to a “new” “hypothesis of neuroplasticity” [18].
This hypothesis links the changes in depression models to
a decrease of brain-derived neurotrophic factor (BDNF)
and the antidepressant effect to an increase in BDNF in
hippocampus [18, 19, 151, 152].Moreover, the decreasedBDNF
observed in heterozygous knock-out mice (BDNF+/−) is
related to a depression-like phenotype [18]. These changes
in brain BDNF expression are paralleled by serum levels,
so that it has been proposed as a biomarker for depression
disease, positive or negative response of the individuals to
the antidepressant treatment [153–156], and even a marker
of suicidal depression [157]. However, the role of BDNF is
still not clear in the depressive pathology since some authors
describe a lack of changes on the BDNF levels associated to
stress animal models [57, 158–160].
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The infusion of BDNF in brain [161, 162] or more specif-
ically in hippocampus [163, 164] produces antidepressant-
like effects. Moreover, within the hippocampus, the infu-
sion of BDNF in the DG but not in the CA1 region pro-
duces an antidepressant-like effect [163], which is supported
by the lack of antidepressant action in mice selectively
knocked out for the BDNF gene in the DG and not in
the CA1 [160]. Even peripherally administered BDNF is
able to display antidepressant-like actions [165], resembling
the increased serum BDNF observed after antidepressant
treatments [166].
Chronic administration of antidepressants produces an
increase in hippocampal BDNF mRNA expression and
BDNF protein levels (Figure 2) [8, 65, 167]. The blockade
of 5-HT
2A receptor reverses the effect of stress-induced
downregulation of BDNFmRNA expression in hippocampus
[168]. Also, the subchronic treatment with SSRI and 5-HT
2A
antagonists is able to increase BDNF expression in the dentate
gyrus of the hippocampus; however, the protein level is not
yet modified in subchronic treatments (Figure 2) [83].
The main role of BDNF regarding adult neurogenesis is
not linked to proliferation, but to the increase in cell survival,
as described using BDNF and its receptor TrkB knock-out
animals which present a reduced BDNF expression [61, 169].
BDNF is implicated in synaptic plasticity, and proteins as
neuritin that are induced by BDNF are decreased in stress-
induced animal models of depression [170] and increased
after chronic antidepressant treatment, contributing to the
BDNF antidepressant effect [170, 171].
The existence of a single-nucleotide polymorphism (SNP)
in the human BDNF gene, BDNF (Val66Met) is associated to
reduced BDNF secretion [172], and to an increased incidence
of neuropsychiatric disorders [173, 174]. In animals BDNF
(Val66Met) predisposes to a depression-like behaviour after
stress situations that recover normal values after the admin-
istration of antidepressants [175]. This polymorphism is also
associated to nonresponders after antidepressant treatment
[176].
Other important trophic factor is the vascular endothelial
growth factor (VEGF) implicated in the “vascular niche
hypothesis of adult neurogenesis.” This theory proposes the
need of vascular recruitment associated to active sites of
neurogenesis formed by proliferative cells that present an
endothelial phenotype in 37% of the cases [177]. VEGF
expression is reduced in hippocampal dentate gyrus after
irradiation [178], and in stress models [179] although other
authors do not show changes associated to stressed animal
models [180]. From studies using irradiated rats, it was
proposed that the decrease of progenitor cells responsible for
the expression of VEGF would underlie the decrease of this
factor [178].
Some antidepressant treatments, as the electroconvulsive
therapy (ECS) [178, 181, 182], approache with antidepressant-
like effect as exercise [180], or mood stabilizers as lamot-
rigine [183], result in the upregulation of VEGF expression.
Moreover, the local administration of this trophic factor
produces an increase in hippocampal proliferation [178].
In addition, the silencing of hippocampal VEGF [184] or
the use of antagonists for its receptor Flk-1 [180] blocks its
antidepressant-like effect and decreases markers of newborn
neurons as doublecortin (DCX).
Even though these data indicate the importance of VEGF
brain levels in the depressive disorder, preliminary reports do
not show a clear correlation between peripheral VEGF and
depressive disorders, not allowing for the use of this molecule
as a marker of depression and/or antidepressant response
[185, 186].
The activation of receptor tyrosine kinases by neu-
rotrophic factors promotes the activation of the PI3K/Akt
pathway that is linked to the Wnt/𝛽-catenin through the
inhibition of GSK-3𝛽 and to the mTOR pathway through the
phosphorylation of mTOR protein [187] that are discussed
below. The PI3K/Akt pathway per se has an outstanding
role in promoting adult hippocampal proliferation and the
inhibition of cell differentiation [188]. Antidepressant treat-
ments also produce increases in Akt levels in structures as
hippocampus [8, 10] and frontal cortex [27].
3.3. Intracellular Pathways
3.3.1. Cyclic Adenosine Monophosphate (cAMP) Cascade.
The upstream and downstream components of the cAMP
signaling pathway have been extensively involved in the
pathophysiology of mood disorders as well as in the actions
of antidepressant drugs. Alterations in several elements of
this pathway, such as G proteins (Gs or Gi), adenylate cyclase
(AC), cAMP levels, cAMP-dependent protein kinase (PKA),
and the cAMP response element-binding protein (CREB)
transcription factor, have been described in peripheral cells
and the postmortembrain of patients with affective disorders,
both untreated or after antidepressant therapy [11, 100, 189,
190]. Various elements along this pathway have been identi-
fied as potential targets for antidepressant drugs (Table 2).
In peripheral cells and postmortem brains of patient with
mayor depression, there is a reduction of the adenylyl cyclase
(AC) activity in response to forskolin [87],𝛽
2
-adrenergic ago-
nists [88–93], and 𝛼2-adrenoceptor agonists [94]. Chronic
treatment with antidepressant drugs produces the increase
in cAMP levels in rat hippocampus, cortex, and striatum, as
well as in postmortem human frontal cortex samples from
depressed patients (Figure 3(a); personal observation). This
effect has been attributed to both enhanced coupling of Gs
proteins to adenylyl cyclase and increased adenylyl cyclase
activity [95, 96]. The direct injection of cAMP or inhibition
of cAMP degradation by rolipram produces antidepressant-
like effect in animals [99]. Chronic antidepressant treatment
in rat desensitizes cAMP response to serotonergic receptor as
5-HT
1A receptor (Figure 3(b)) and 5-HT4 receptor [8, 97, 98]
and increases the CB1-mediated inhibition of adenylyl cyclase
(AC) in prefrontal cortex, an effect that is modulated by
5-HT
1A receptors [100].
The next step in this signaling pathway is the activation
of cAMP-dependent protein kinase (PKA) by cAMP, so
that PKA activity is increased after chronic antidepressant
administration [101]. Active PKA phosphorylates proteins as
CREB, a transcription factor that regulates the expression of
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Figure 2: BDNFmRNA expression (a) and protein level (b) in the dentate gyrus of the hippocampus (DG) or total hippocampus, respectively,
after 7-day treatment with the 5-HT
4
partial agonist RS67333 (1.5mg/kg/day) (modified from [8]) and 7-day coadministration of the SSRI
fluoxetine (5mg/kg/day) and the 5-HT
2A antagonist ketanserin (0.1mg/kg/day).
∗𝑃 < 0.05 versus vehicle. Modified from Pascual-Brazo et
al., 2012 [8], and Pilar-Cue´llar et al., 2012 [83].
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Figure 3: Antidepressant treatment increases basal cAMP in both rat and human. (a) Increase of basal cAMP levels in rat hippocampus,
frontal cortex and striatum after chronic (14 days) antidepressant treatment with fluoxetine (10mg/kg/day) and venlafaxine (40mg/kg/day),
and subchronic treatment (3 days) with the 5HT
4
agonist RS67333 (1.5mg/kg/day) and in postmortem frontal cortex samples from control,
antidepressant free-depressed subjects (AD-free MD) and antidepressant-treated depressed subjects (AD-treated MD). cAMP is expressed
in pmoles/mg protein. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 versus vehicle or control subjects; ∙∙𝑃 < 0.01 versus antidepressant-free
depressed subjects. (b)Modulation of 5-HT
1A receptor subtype-mediated inhibition of cAMP accumulation by antidepressant drugs. Chronic
antidepressant treatment with fluoxetine (10mg/kg/day) and venlafaxine (40mg/kg/day) for 14 days downregulates 8-OH-DPAT inhibition
of forskolin-induced cAMP accumulation. (a) Modified fromMostany et al., 2008 [10], Pascual-Brazo et al., 2012 [8], and unpublished results
and (b) unpublished results.
several genes involved in neuroplasticity, cell survival, and
cognition [191–195].
CREB has been widely involved in the pathophysiology
of depression and both behavioural and cellular responses
to antidepressant treatments [11, 190]. Hippocampal expres-
sion of CREB is reduced in response to stress exposure
[102, 103]. In contrast, chronic but not acute antidepressant
therapy and electroconvulsive shock (ECS) increase levels of
CREBmRNA, CREB protein (Figure 4), and CREB activity—
promoting the phosphorylation of this protein—effects that
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Figure 4: Western blot analyses of hippocampal CREB (a) and p-CREB (b) levels and ratio p-CREB/CREB (c) after chronic antidepressant
treatment (14 days) with fluoxetine (10mg/kg/day) and venlafaxine (40mg/kg/day). Note that p-CREB levels and ratio p-CREB/CREB are
increased after fluoxetine treatment, but not total CREB, or after venlafaxine treatment in total cell lysate from hippocampus of rats. Values
are means ± S.E.M. Corresponding to densitometry levels of the proteins expressed as the percentage of the same proteins in vehicle-treated
animals. ∗𝑃 < 0.05 versus vehicle. Modified fromMostany et al., 2008 [10], and Mato et al., 2010 [100].
seems to be area and drug dependent [11, 103, 105–108].
Thus, increased phosphorylated CREB levels in hippocam-
pus are linked to antidepressant-like behaviour [44], as
observed after viral-mediated overexpression of CREB in
hippocampus in behavioural models of depression [44].
Contrary to what could be expected, CREB overexpression
in the nucleus accumbens produces prodepressive effects
[111], and lowered CREB in the nucleus accumbens in mice
exhibits an antidepressant-like response [196]. A different
pattern appears also for amygdala, in which high CREB
levels produce opposite effects depending on the timing.
Thus, when CREB overexpression is induced before learned
helplessness training, there is a prodepressant effect, while the
increase of CREB after the training is antidepressant [109].
Studies in postmortem human brain indicate lower levels of
CREB protein in depressed antidepressant-free subjects, in
contrast to the increased CREB level in patients taking an
antidepressant at the time of death [104]. These results are
parallel to studies in human fibroblasts of patients withmajor
depression [110], which is consistent with animal studies.
Among the several target genes regulated by CREB, two of
the more relevant, are the brain-derived neurotrophic factor
(BDNF) and the vascular endothelium growth factor (VEGF)
[19, 60, 197, 198].
A growing body of data shows that other signalling cas-
cades can modulate CREB activity through phosphorylation,
such as the calcium/calmodulin-dependent kinase (CaMKII)
and the mitogen-activated protein (MAP) kinase cascades,
and may also be implicated in the mechanism of action of
antidepressants [11, 199].
Initially, all effects of cAMP increase were attributed to
the activation of PKA/CREB, but two novel targets as the
cAMP-regulated ion channels and Epac (exchange protein
directly activated by cAMP) are now known to be involved
in mediating cAMP responses. An increase in Epac-2 levels,
but not Epac-1, has been found in postmortem samples of
prefrontal cortex and hippocampus of depressed subjects
[112].
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3.3.2. Wnt/𝛽-Catenin Pathway. The Wingless-type (Wnt)
family of proteins has key roles in many fundamental
processes during neurodevelopment [200]. The role of this
pathway in neural development, through the modulation of
neural stem cells’ (NSC) proliferation and differentiation,
has been clearly demonstrated [201]. Some of the processes
regulated by Wnt/𝛽-catenin pathway activity are neural
differentiation [202], hippocampal formation [203, 204],
dendritic morphogenesis [205, 206], axon guidance [207,
208], and synapse formation [209]. Moreover, it also plays
an important role in spatial learning [210] and memory,
including long-term potentiation (LTP) phenomena [159].
In the absence of Wnt signaling, 𝛽-catenin function is
blocked by a destruction complex consisting of Axin, APC,
andGSK-3𝛽 andCK1a kinases [211], which phosphorylates𝛽-
catenin for destruction in the proteasome [212, 213]. Wnts act
through both canonical and noncanonical signal transduc-
tion pathways. Canonical Wnt signaling results in the inhibi-
tion of GSK-3𝛽 which is constitutively active, and the non-
phosphorylated 𝛽-catenin is stabilized in the cytoplasm and
translocated to the nucleus, which is essential for canonical
Wnt signaling [214]. Once in the nucleus, 𝛽-catenin forms
a complex with the T-cell factor/lymphoid enhancer factor
(TCF/LEF) transcription factors, to activate the expression of
Wnt target genes. TCF/LEF transcription factors are bound
to Groucho, a protein producing repressive effects [214].
Nuclear 𝛽-catenin promotes the displacement of Groucho
and the binding of the histone acetylase cyclic AMP response
element-binding protein (CREB), activating the transcription
machinery [214, 215].Thenoncanonical pathway or𝛽-catenin
independent is mediated through Rac/Rho (Wnt/PCP) or
through calcium (Wnt/Ca2+) [201].
In the last years several evidences have implicated Wnt-
signaling pathway in the pathophysiology and treatment of
mood disorders and other cognitive pathologies. GSK-3𝛽
and 𝛽-catenin are regulated either directly or indirectly by
lithium, valproate, antidepressants, and antipsychotics [8, 10,
113–117], while GSK-3𝛽 has also been identified as a target for
the treatment of Alzheimer’s disease [216] (Table 2).
Postmortem human brain samples from depressed sub-
jects and teenage suicide victims present a dysregulation of
Wnt/GSK-3𝛽 signaling with a decrease in 𝛽-catenin expres-
sion in prefrontal cortex [124]. 𝛽-catenin knock-out mice
with 50–70% decrease of 𝛽-catenin expression in forebrain
regions present an increased immobility time in the tail
suspension test indicating a depression-like state, but not in
other anxiety tests [125].
The inhibition of GSK-3𝛽 activity, either pharmacolog-
ically [117–119], or through deletion in mouse forebrain,
results in an increase in brain 𝛽-catenin levels, as well as
in antidepressant-like effects or decreased anxiety [120], as
observed by the direct overexpression of 𝛽-catenin in mouse
brain [126]. GSK-3𝛽 inhibition by lithium is an important
regulator of cell survival related to mood stabilizers [215]
and displays antidepressant efficacy [115, 118, 215, 217, 218].
In contrast, GSK-3𝛽 knockin mice displayed increased sus-
ceptibility to stress-induced depressive-like behaviour [121],
presenting decreased cell proliferation in the subgranular
zone of the dentate gyrus, accompanied by a reduction in
VEGF, but not BDNF, and blunted neurogenesis in response
to antidepressant treatments [219]. These data support the
importance of the Wnt pathway activation and 𝛽-catenin
levels associated to mood disorders and their treatment. In
addition, SNP variation in the promoter region of GSK-3𝛽
plays a protective role in the onset of bipolar illness [122] and
increased antidepressant response [123].
Recent studies have identified the Wnt/GSK-3𝛽/𝛽-
catenin-signaling pathway as a key regulator of adult
neurogenesis in hippocampus [220, 221] or subventricular
zone [222], highlighting the role of GSK-3𝛽 on neural
progenitor homeostasis [200]. Wnt proteins are signaling
molecules that are released from hippocampal neural stem
cells (NSC) and astrocytes, acting autocrinally to regulate
proliferation via Wnt canonical pathway [220, 221].
Wnt/𝛽-catenin pathway is activated by antidepressant
treatments as electroconvulsive therapy [26], chronic
treatments with classical antidepressants as the dual
serotonin-noradrenaline reuptake inhibitor (SNRI)
venlafaxine (Figure 5(a)) [10], and 5-HT
4
partial agonists [8].
The antidepressant-induced 𝛽-catenin increase is observed
in the subgranular zone (SGZ) of the dentate gyrus (DG)
of the hippocampus, in membrane and nuclear fractions
[10, 26]. The increased proliferation observed in SGZ after
chronic antidepressant treatments is localized in cell clusters
that also show a positive 𝛽-catenin staining [8, 10].
Other treatments with antidepressant-like efficacy, such
as the subchronic administration of SSRI fluoxetine together
with the 5-HT
2A antagonist ketanserin, also produce a 𝛽-
catenin increase in the membrane fraction but not in the
nuclear one, which corresponds with a lack of changes in
hippocampal proliferation (Figure 5(b)) [83]. The increase
in membrane-associated 𝛽-catenin is parallel to an eleva-
tion of N-cadherin protein [83], both members of the 𝛽-
catenin/N-cadherin complex present in pre- and postsynap-
tic terminals [223, 224], where 𝛽-catenin recruits scaffold-
ing proteins [225], conforming cell-cell adhesion complexes
[226], recruiting synaptic vesicles [209, 227], and acting on
the development of new synapses [225]. This suggests a
preference of modifications in synaptic plasticity instead of
proliferation, as previously reported for other antidepressant
treatments [60].
In addition, Frizzled receptors and GPCRs can interact
through several pathways [228, 229]. Some GPCRs act
through Gq and/or Gi proteins activating PKB (protein
kinase B)/Akt which inhibits GSK-3𝛽 via phosphorylation.
These receptors can also activate Gs proteins that activate
prostaglandin E2 (PGE2), phosphoinositide 3-kinase (PI3K),
and PKB/Akt, leading to the inhibition of GSK-3𝛽. Other
receptors act on Gq or G12/13 proteins, activating the phos-
pholipase C𝛽 (PLC𝛽) and protein kinase C (PKCs) and
inhibiting GSK-3𝛽 [228]. Taken together, these data support
the possible existence of interactions between the GSK-
3𝛽/𝛽-catenin pathway and other neurotransmitter systems
involved in depression, including serotonin. The pharmaco-
logical modulation of the different elements of the Wnt/𝛽-
catenin pathway with antidepressant purposes has to be
clarified in the near future, probably modulating at the
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Figure 5: Implication on 𝛽-catenin subcellular distribution of the chronic (14 days) antidepressant treatment with the SNRI venlafaxine
(40mg/kg/day) (a), and 7-day treatment with the SSRI fluoxetine (5mg/kg/day), the 5-HT
2A antagonist ketanserin (0.1mg/kg/day), and the
combination of both (b). Note that chronic treatment with venlafaxine produces an increase in both membrane-associated and nuclear 𝛽-
catenin, while the subchronic treatmentwith fluoxetine + ketanserin, only increases𝛽-catenin in themembrane but not in the nuclear fraction.
∗𝑃 < 0.05 and ∗∗∗𝑃 < 0.001 versus vehicle. (a) Modified fromMostany et al., 2008 [10], and (b) modified from Pilar-Cuellar et al., 2012 [83].
level of Wnts or 𝛽-catenin activity. Interestingly, a number
of patents regarding GSK-3𝛽 inhibition as the therapeutic
mechanism for treatment of neuropsychiatric disorders are
being launched, including treatment of depression.
3.3.3. mTOR Pathway. Target of rapamycin (TOR) genes,
members of the phosphoinositol kinase-related kinase
(PIKK) family of kinases [230], was first described in yeast
as the pharmacological targets of the microbicide rapa-
mycin [231]. TORs were subsequently described in other
invertebrate and vertebrate organisms. mTOR, the mamm-
alian form of this protein, exists in two different functional
multiprotein complexes within the cells, mTORC1 and
mTORC2, which are evolutionarily conserved from yeast to
mammals [232, 233]. mTORC2 is involved in cytoskeletal
remodeling [234] and in the regulation of cell survival
and cell cycle progression. mTORC1, the primary target
of rapamycin, is involved in cell proliferation, cell growth
and survival by protein translation, energy regulation, and
autophagy in response to growth factors, mitogens, nutrients,
and stress [235–237].
In neurons, mTORC1 activity is regulated by phospho-
rylation in response to growth factors, as BDNF, mitogens,
hormones, and neurotransmitters through the activation ofG
protein-coupled receptors (GPCRS) or ionotropic receptors.
The mTORC1 phosphorylation is mediated by ERK/MAPK,
PI3K, PKA, and Epac. The activation of mTORC1 results in
the phosphorylation and activation of several downstream
targets as the eukaryotic initiation factor 4E-binding protein
1 (4E-BP1), p70 ribosomal S6 kinase (p70S6K), RNA helicase
cofactor eIF4A, extracellular signal-regulated kinase (ERK,
including both ERK1 and ERK2), or PKB/Akt; and the
inhibition of the eukaryotic elongation factor 2 kinase (eEF2)
[238, 239].
mTOR has been extensively studied related to cancer,
development, metabolism, and more recently to the central
nervous system (CNS) physiology and diseases [238, 240,
241].mTOR-signaling pathway is involved in synaptic plastic-
ity, memory retention, neuroendocrine regulation associated
with food intake and puberty, and modulation of neuronal
repair following injury. The target proteins of mTOR, 4E-
BP1, and eukaryotic initiation factor-4E (eIF4E) have been
detected in cell bodies and dendrites in cultured hippocampal
neurons and their distribution completely overlaps with the
postsynaptic density protein-95 (PSD-95) at synaptic sites,
suggesting the postsynaptic localization of these proteins
[242]. The activation of mTOR has been functionally linked
with local protein synthesis localized presynaptically as
synapsin I, or postsynaptically as PSD-95 and GluR1, and
cytoskeletal proteins as the activity-regulated cytoskeletal-
associated protein (Arc) [27, 241, 243].
mTOR-signaling pathway has been also related to a
number of neurological diseases, such as Alzheimer’s dis-
ease, Parkinson’s disease, and Huntington’s disease, tuberous
sclerosis, neurofibromatosis, fragile X syndrome, epilepsy,
brain injury, and ischemic stroke [244]. Dysfunction of
mTORC1 is associated with the pathogenic mechanisms of
Alzheimer’s disease, and the activation of p70S6K, down-
stream of mTORC1, has been identified as a contributor
to hyperphosphorylated tau accumulation in neurons with
neurofibrillary tangles [245].
Recent studies have also associated mTOR signaling
in affective disorders since the administration of ketamine
produces a fast-acting antidepressant-like effect in animals
[27] and human [131]. In stressed rats, a reduction in PI3K-
Akt-mTOR-signaling pathway has been reported in PFCx
[127, 128] or amygdala [129]. The inhibition in mPFCx
of calcineurin, a serine/threonine protein phosphatase that
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participates in the regulation of neurotransmission, neuronal
structure and plasticity, and neuronal excitability, induces a
depression-like behaviour [246], accompanied by a decrease
inmTOR activity [130].This effect can be reverted by the acti-
vation of mTOR by NMDA or the chronic administration of
the antidepressant venlafaxine, promoting an antidepressant-
like effect [130]. In human postmortem samples of prefrontal
cortex of depressed subjects, there is a decrease in the
expression of mTOR, as well as some of the downstream
targets of this pathway, as p70S6 kinase (p70S6K), eIF4B,
and its phosphorylated form, which suggests the impairment
of the mTOR pathway in major depressive disorder (MDD)
that would lead to a reduction in protein translation [247]
(Table 2).
The subchronic, but not acute, administration of rapa-
mycin in rodents has an antidepressant-like effect shown in
two behavioural tests as forced swimming and tail suspension
tests [248]. Acute administration of differentNMDA receptor
antagonists as the ketamine [27], Ro 25-6981 [27], and MK-
801 [249] or antagonists of the group II of the metabotropic
glutamate receptors (mGlu2/3), as MGS0039 and LY341495,
produce a fast antidepressant effect [250, 251] mediated
by mTOR-signaling pathway activation. Ketamine rapidly
activates the mammalian target of rapamycin (mTOR) path-
way, increases synaptogenesis, including increased density
and function of spine synapses, in the prefrontal cortex of
rats [27, 243], and increases hippocampal BDNF expression
[252], that results in a rapid antidepressant-like effect in
rats [27, 243] and humans [253]. Moreover, blockade of
mTOR signalling by the specific antagonist rapamycin com-
pletely blocks the ketamine induction of synaptogenesis and
behavioural responses in models of depression [27]. Other
antidepressant strategies as the electroconvulsive treatment
(ECT) also activate themTORpathway, leading to an increase
in VEGF [254]. Therefore, modulation of mTOR could be
a novel approach to develop strategies for the treatment of
affective disorders [255].
4. A Further Step: Neuroplasticity
versus Proliferation
The neurogenesis hypothesis of depression was based upon
the demonstration that stress decreased adult neurogenesis
in the hippocampus. This reduction in the production of
newborn granule cells in the hippocampal dentate gyrus is
related to the pathophysiology of depression. Since then,
several studies have established that newborn neurons in the
dentate gyrus are required for mediating some of the bene-
ficial effects of antidepressant treatments since the increase
in cell proliferation after antidepressant treatment is only
observed in the SGZ and not in SVZ, suggesting a specificity
of the antidepressants to regulate hippocampal neurogenesis.
Moreover, psychotropic drugswithout antidepressant activity
do not increase neurogenesis [135, 256]. The disruption of
hippocampal proliferation by irradiation is not sufficient to
drive a depression-like phenotype. Both X-irradiation and
genetic manipulation approaches demonstrated a require-
ment of hippocampal neurogenesis in mediating some of
the antidepressant treatment effects [71, 76, 257], while mice
exposed to X-irradiation of the SVZ or cerebellum responded
normally to the antidepressants. However, some drugs with
potential antidepressant action do not mediate their effect
through the increase in hippocampal proliferation, as drugs
acting on corticotrophin releasing factor receptor (CRF) or
arginine vasopressin 1b (V1b) receptors [76], as indicated
previously.
The appearance of the antidepressant-like effect in
behavioural tests after 2-3 weeks parallels the time needed for
the growth of newborn cells in hippocampus [258]. However,
this time course does not always take so long. For classic
antidepressants as the serotonin transporter inhibitors, a
chronic regime is needed to observe that increased prolifera-
tion rate [10, 60], while, for others as ECS and 5-HT
4
agonists
[8, 64], an acute or subacute treatment, respectively, is enough
to increase proliferation.
The putative role of changes in synaptic plasticity and/or
neural proliferation in the depressive pathology is proposed
some time ago [19]. Synaptic plasticity, as indicated for prolif-
eration, is also modulated by antidepressant treatments [43,
44].The neural plasticity is not only functional but structural
and is impaired in animal models [259]. For example, there
is a decrease in spine number in hippocampal CA1 and
CA3 areas in bulbectomized animals that are reverted with
antidepressant treatment [259–261]. This structural plasticity
is more striking when new neurons are born [53], or there
is an increase in neuron survival as a consequence of
antidepressant treatment or ECS [262]. The new dendritic
spines formed are associated to smaller postsynaptic densities
(PSDs) and a higher frequency ofminiexcitatory postsynaptic
currents (mEPSCs), suggesting an increased number of new
and active glutamatergic synapses [263].
The rapid antidepressant response to drugs as ketamine
acting through the blockade of NMDA receptors appears as
a new target for having fast-acting effects on the treatment of
mood disorders compared to the weeks or months required
for standard medications. Ketamine and other glutamate
antagonists through the increase of the number and func-
tion of new spine synapses in rat prefrontal cortex by the
activation of mTOR [27] do not modify hippocampal cell
proliferation [264].
It would also be critical for future work to validate the
relative importance of antidepressant-induced neurogenesis
and synaptic plasticity in the antidepressant effects. However,
evidence is strong that neurogenesis is required for at least
some of the beneficial effects of antidepressant treatment.
The exact role of neuroplastic/neuroproliferative changes in
other brain structures as mPFCx and amygdala should be
elucidated.
5. Conclusion
As indicated in this review, the importance of either prolifer-
ation or plasticity, or both, is still a matter of debate. As the
involvement of proliferation and plasticity has been mainly
studied in hippocampus,wemight be underestimating its role
in the antidepressant effect. In this sense, as the hippocampus
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is responsible for the learning and cognition part of the
depressive disorder, the fact that the impairment of hip-
pocampal proliferation would not block the antidepressant
effect of some drugs does not necessarily conclude that the
proliferation is only dependent on hippocampus. In the last
years, prefrontal cortex, a structurewith a great importance in
mood control andworkingmemory, is gaining increasing rel-
evance in the plastic changes linked to antidepressant effects
promoted by drugs as ketamine. In this sense, hippocampal
proliferation would be only a small part of the plastic changes
that are taking placewithin the hippocampus, and other brain
areas. Thus, we must not underestimate the implication of
synaptic plasticity in those antidepressant treatments that are
not accompanied with increased proliferation.
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